文献速递脑血管病

2015—2019年中国不同地区卒中诊疗绩效指标依从性:中国卒中中心联盟证据

Adherence to Stroke Care Performance Measures in Different Regions in China, 2015-2019: Evidence From the Chinese Stroke Center Alliance.
PubMed 文献 · Neurology · 2022-08-02

该回顾性观察研究利用中国卒中中心联盟2015年8月至2019年8月数据,纳入1473家医院的838229例急性缺血性卒中患者,评估11项指南推荐治疗的依从性。非卒中带地区(南方)的总体复合评分(0.77 vs 0.75)和全部或全无指标(25.5% vs 22.0%)均高于卒中带地区(北方)。东部和中部在静脉溶栓、早期抗栓、降脂及深静脉血栓预防等方面优于西部,且卒中带分区与经济发展分区存在交互效应。

要点

  • 非卒中带(南方)总体复合评分0.77 vs 卒中带(北方)0.75,全部或全无指标25.5% vs 22.0%。
  • 非卒中带吞咽筛查OR 1.82(95%CI 1.55-2.13,p<0.001),康复评估因经济水平而异。

核心结论

  • 卒中诊疗绩效指标依从性沿卒中带分区和经济发展分区存在地区差异,非卒中带地区总体诊疗质量高于卒中带地区。
  • 两个分区对若干单项指标存在交互效应。

研究设计与样本

  • 回顾性观察研究,使用中国卒中中心联盟2015年8月至2019年8月数据。
  • 纳入1473家医院的838229例急性缺血性卒中患者。
  • 主要结局为医院人员对11项指南推荐治疗的依从性,共同主要结局包括复合评分(范围0[不依从]至1[完全依从])和全部或全无二分类结局。
  • 采用多变量广义估计方程回归模型分析。

主要发现

  • 非卒中带地区(南方)复合评分0.77 vs 卒中带地区(北方)0.75,调整OR 1.03(95%CI 1.02-1.04,p<0.001)。
  • 非卒中带地区全部或全无指标25.5% vs 卒中带地区22.0%,OR 1.32(95%CI 1.17-1.49,p<0.001)。
  • 与西部相比,东部静脉溶栓OR 1.81(95%CI 1.51-2.18,p<0.001),中部OR 1.57(95%CI 1.26-1.95,p<0.001)。
  • 与西部相比,东部早期抗栓OR 1.77(95%CI 1.49-2.11,p<0.001),中部OR 1.37(95%CI 1.12-1.66,p<0.001)。
  • 与西部相比,东部降脂OR 1.29(95%CI 1.08-1.53,p<0.001),深静脉血栓预防OR 1.28(95%CI 1.08-1.50,p=0.003)。

关键数值与推荐

  • 非卒中带地区吞咽筛查OR 1.82(95%CI 1.55-2.13,p<0.001)。
  • 东部非卒中带地区抗凝OR 1.62(95%CI 1.34-1.96,p<0.001),抗栓OR 0.63(95%CI 0.52-0.77,p<0.001),抗糖尿病药OR 0.87(95%CI 0.77-0.99,p=0.03)。
  • 西部非卒中带地区抗高血压药OR 0.64(95%CI 0.46-0.88,p=0.004),抗糖尿病药OR 0.66(95%CI 0.54-0.81,p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To explore the regional discrepancy of the adherence to guideline-recommended stroke interventions for the stroke belt division (north vs south), the economic development division (east vs middle vs west), and potential interaction. METHODS: We conducted a retrospective observational study using data from the Chinese Stroke Center Alliance from August 2015 to August 2019. The primary outcome was hospital personnel adherence to 11 individual guideline-recommended treatments. The coprimary outcomes included 2 summary measures: a composite score (range, 0 [nonadherence] to 1 [perfect adherence]) and an all-or-none binary outcome for adherence to evidence-based stroke. Regional disparities were assessed according to the stroke belt division and the economic development division and the interaction between these 2 divisions. Multivariate regression models with generalized estimating equations were used to analyze the outcomes. RESULTS: This study included 838,229 patients with acute ischemic stroke from 1,473 hospitals. The overall quality of care in the nonbelt regions (southern China) was higher than in the stroke belt regions (northern China), as reflected by a higher composite score (0.77 vs 0.75; adjusted odds ratio 1.03 [95% CI 1.02-1.04]; p < 0.001) and a higher all-or-none measure (25.5% vs 22.0%; 1.32 [1.17-1.49], p < 0.001). Patients in the East and Central had higher odds of using intravenous tissue-type plasminogen activator (East: 1.81 [95% CI 1.51-2.18], p < 0.001; Central: 1.57 [95% CI 1.26-1.95], p < 0.001), early antithrombotic medications (East: 1.77 [1.49-2.11], p < 0.001; Central: 1.37 [1.12-1.66], p < 0.001), lipid-lowering medications (East: 1.29 [1.08-1.53], p < 0.001), and deep vein thrombosis prophylaxis (East: 1.28 [1.08-1.50], p = 0.003) compared with those in the West. Patients in the nonbelt regions had higher odds of getting dysphagia screening (1.82 [1.55-2.13], p < 0.001) and rehabilitation assessment (which though varied among different economic development levels). Reflected by significant interaction effects, for patients in the East, those in the nonbelt regions had greater odds of receiving anticoagulation (1.62 [1.34-1.96]; p < 0.001) but lower odds of receiving antithrombotic (0.63 [0.52-0.77]; p < 0.001) and antidiabetic medications (0.87 [0.77-0.99]; p = 0.03); for patients in the West, those in the nonbelt regions were less likely to receive antihypertensive (0.64 [0.46-0.88]; p = 0.004) and antidiabetic (0.66 [0.54-0.81]; p < 0.001) medications. DISCUSSION: Stroke care performance measures differed across regions, along the stroke belt division, and the economic development division. The overall quality of care in the non-stroke belt regions was higher than that in the stroke belt regions. The 2 divisions had interaction effects on several individual measures.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Zheng S, Zhang T, Gu HQ, et al. Adherence to Stroke Care Performance Measures in Different Regions in China, 2015-2019: Evidence From the Chinese Stroke Center Alliance. Neurology. 2022. PMID: 35918168. doi:10.1212/WNL.0000000000201024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。